Needham & Company Maintains a 'Buy' on Brooks Automation (BRKS); Acquisition of Nexus Biosystems Should Accelerate Life Science Effort

Needham & Company maintains a 'Buy' on Brooks Automation Inc. (NASDAQ: BRKS) price target of $13.00.

Needham analyst says, "Yesterday after market close, BRKS announced the acquisition of Nexus Biosystems, Inc., a privately-held life science equipment company. We believe the latest acquisition is an important second step for BRKS to transform its business from a semi-focused, sub-system supplier to a diversified provider of automation equipment and technology. By targeting the
growing market of compound sample management in the life science space, we believe BRKS is moving up the value chain, ultimately increasing the value of the company. While the transition will require additional investments, limiting near-term earnings, we believe long-term investors will be rewarded as BRKS grows into the life science space."

For more ratings news on Brooks Automation Inc. click here and for the rating history of Brooks Automation Inc. click here.

Shares of Brooks Automation Inc. closed at $10.60 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Super Micro Computer (SMCI) Falls 6%
• Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
• JD.com, Inc (JD) PT Lowered to $25 at Morgan Stanley